Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 9/20 | 0.69 |
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.69 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.60 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.56 |
| ▸ | LPAR6 | P43657 | 5/20 | 0.56 |
| ▸ | LPAR4 | Q99677 | 5/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
| ▸ | PRKCB | P05771 | 1/20 | 0.51 |
| ▸ | PRKCA | P17252 | 1/20 | 0.51 |
| ▸ | PRKCH | P24723 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | PRKCI | P41743 | 1/20 | 0.51 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.51 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.51 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.51 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.51 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Monoethanolamine SCHEMBL27910098 | 0.89 | LPAR1 (0.64) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| Glycerin SCHEMBL28048922 | 0.89 | LPAR1 (0.64) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| Monoethanolamine SCHEMBL28048917 | 0.89 | LPAR1 (0.64) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| Choline SCHEMBL28147311 | 0.85 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| Choline SCHEMBL28271776 | 0.85 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| Choline SCHEMBL28104751 | 0.85 | LPAR1 (0.60) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| SCHEMBL7588441 | 0.85 | LPAR1 (0.77) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| SCHEMBL10715915 | 0.84 | LPAR3 (0.61) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| Serine SCHEMBL27927630 | 0.83 | LPAR1 (0.57) | LPAR1LPAR3LPAR2LPAR5LPAR6 | |
| SCHEMBL2732573 | 0.83 | LPAR3 (0.97) | LPAR1LPAR3LPAR2LPAR5LPAR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220023447-A1 | FIBRIN-TARGETED POLYMERIZED SHELL LIPID MICROBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | NANOVALENT PHARMACEUTICALS INC (US) | 2022-01-27 | — | — | US | disclosed |
| US-10413871-B2 | Stabilization of biomimetic membranes | DANISCO US INC (US) | 2019-09-17 | — | — | US | disclosed |
| EP-2909230-B1 | STABILIZATION OF BIOMIMETIC MEMBRANES | DANISCO US INC (US) | 2019-05-22 | — | — | EP | disclosed |
| US-20190099725-A1 | STABILIZATION OF BIOMIMETIC MEMBRANES | DANISCO US INC (US) | 2019-04-04 | — | — | US | disclosed |
| US-10226744-B2 | Stabilization of biomimetic membranes | DANISCO US INC (US) | 2019-03-12 | — | — | US | disclosed |
| EP-2341933-B1 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2017-11-22 | — | — | EP | disclosed |
| US-20150273407-A1 | STABILIZATION OF BIOMIMETIC MEMBRANES | DANISCO US INC. | 2015-10-01 | — | — | US | disclosed |
| EP-2909230-A1 | STABILIZATION OF BIOMIMETIC MEMBRANES | Danisco US Inc. (US) | 2015-08-26 | — | — | EP | disclosed |
| US-8946421-B2 | Lipidated imidazoquinoline derivatives | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2015-02-03 | — | — | US | disclosed |
| US-20140323731-A1 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2014-10-30 | — | — | US | disclosed |
| US-20140199233-A1 | Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2014063097-A1 | STABILIZATION OF BIOMIMETIC MEMBRANES | DANISCO US INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-8624029-B2 | Lipidated imidazoquinoline derivatives | GLAXOSMITHKLINE BIOLOGICALS S.A. (BE) | 2014-01-07 | — | — | US | disclosed |
| US-20130129635-A1 | POLYMERIZED SHELL LIPID MICROBUBBLES AND USES THEREOF | Wilson Sonsini Goodrch & Rosati (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2011149985-A1 | POLYMERIZED SHELL LIPID MICROBUBBLES AND USES THEREOF | NANOVALENT PHARMACEUTICALS, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110282061-A1 | Lipidated Imidazoquinoline Derivatives | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2011-11-17 | — | — | US | disclosed |
| EP-1056473-B1 | TARGETED DELIVERY OF BIOLOGICALLY ACTIVE MEDIA | BRACCO RESEARCH SA (CH) | 2005-05-25 | — | — | EP | disclosed |
| US-6258378-B1 | INJECTING SUSPENSION OF MICROBALLOONS CARRYING ENTRAPPED GAS AND LIPOSOME VESICLES FILLED WITH DRUG OR DIAGNOSTIC LIQUID; ULTRASONIC IRRADIATION TO EXPLODE | BRACCO RESEARCH S.A. (CH) | 2001-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323731-A1 | LIPIDATED IMIDAZOQUINOLINE DERIVATIVES | IFNG, IRF3, IFNAR1 | LPAR1 433/4885LPAR3 327/4885LPAR2 385/4885 |
| US-20110282061-A1 | Lipidated Imidazoquinoline Derivatives | IFNG, IRF3, IFNAR1 | LPAR1 432/4885LPAR3 329/4885LPAR2 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.